Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Best Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$1,358,114

415 payments

Through program year 2025, Best Clinical Trials LLC is reported as receiving $1,358,114 in research payments, across 415 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $335,298 25
2024 Research $399,529 127
2023 Research $117,094 55
2022 Research $240,577 186
2021 Research $131,523 13
2020 Research $74,717 5
2019 Research $59,376 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $560,071 35 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $274,223 311 payments
  3. Sage Therapeutics, Inc. $224,162 28 payments
  4. GlaxoSmithKline, LLC. $134,270 30 payments
  5. Pfizer Inc. $79,534 6 payments
  6. Novartis Pharmaceuticals Corporation $67,840 1 payment
  7. Eli Lilly and Company $9,982 2 payments
  8. AbbVie, Inc. $7,031 1 payment
  9. Regeneron Pharmaceuticals, Inc. $1,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $393,222 29 payments
  2. A Study to Evaluate the Efficacy and Safety of Sage-217 in Participants With Severe Postpartum Depression (PPD) $222,902 27 payments
  3. A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Chronic Rhinosinusitis (CRS)With or Without Nasal Polyps $196,576 174 payments
  4. Ph III OLE of Astegolimab in COPD $166,849 6 payments
  5. A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi $134,270 30 payments
  6. A Phase 23 Doubleblind Randomized Placebocontrolled Safety and Efficacy Trial of Bhv3000 Rimegepant Orally Disintegrating Tablet Odt for the Acute Treatment of Chronic Rhinosinusitis CRS With Or Without Nasal Polyps $77,647 137 payments
  7. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $67,840 1 payment
  8. A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $58,376 3 payments
  9. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $21,158 3 payments
  10. F16-974 $7,031 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record